Long Term use of JAK Inhibitors (CTP-543) Shows Promising Results In CoNCERT Pharmaceuticals Study
Anthony Gilding, Science Communication at CANAAF
CANAAF is very pleased to announce this exciting data presented by CoNCERT Pharmaceuticals at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress. The data showed that, as with the previous Phase 2 study results of the CTP-543 clinical trial, hair regrowth assessed by the Severity of Alopecia Tool (SALT) was maintained or improved in the vast majority of patients to date. This is very promising as it suggests that CTP-543 is effective at achieving long-term hair growth in Alopecia Areata. To date, 130 patients have taken CTP-543 for one year, and over 50 patients have taken it for longer than a year. This long-term extension study allows for patients to take the experimental CTP-543 for longer than one year, providing them with a more wholesome clinical benefit.
CTP-543 is a selective oral Janus Kinase (JAK) inhibitor that suppresses the autoimmune response that causes hair loss in Alopecia Areata. The U.S. Food and Drug Administration (FDA) has granted the drug CTP-543 Breakthrough Therapy designation for the treatment of adult patients with moderate to severe Alopecia Areata and Fast Track designation for the treatment of Alopecia Areata. This will allow the clinical trial to proceed more quickly and hopefully lead to the listing of CTP-543 as one of the first treatments dedicated specifically for the treatment of Alopecia Areata.
To date, Alopecia Areata does not have a cure or any specific treatments. Current medical interventions for Alopecia Areata are repurposed medications such as corticosteroids, broad systemic immunosuppressants, or topical calcineurin inhibitors. As such, we’re eagerly waiting for a new, dedicated treatment to arise.
As the clinical trial progresses, CANAAF will keep the Alopecia Areata community informed of new findings.
